| Literature DB >> 32508560 |
Xu Zhang1, Baohu Liu1, Nan Li2, Yuanyuan Li1, Jun Hou1, Guoping Duan1, Dongyu Wu1.
Abstract
OBJECTIVES: Many post-traumatic patients with minimally conscious state are complicated by psychomotor inhibition state (PIS), which impedes further rehabilitation. The treatment of PIS is not satisfactory. This pilot study aimed to investigate effects of anodal transcranial direct current stimulation (A-tDCS) on PIS in post-traumatic patients and examine the altered cortical activation after tDCS using non-linear electroencephalogram (EEG).Entities:
Keywords: brain stimulation; electroencephalogram; neurobehavioral disorder; non-linear dynamics; transcranial direct current stimulation; traumatic brain injury
Year: 2020 PMID: 32508560 PMCID: PMC7251071 DOI: 10.3389/fnins.2020.00386
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
FIGURE 1Transcranial direct current stimulation electrode position.
Clinical characteristics of the patients.
| ID | Age (y) | Duration (d) | Initial diagnosis | MRI/CT findings | GOS |
| 1 | 21–25 | 112 | MCS | Right frontal, left basal ganglia, midbrain hemorrhage | 5 |
| 2 | 31–35 | 167 | MCS | Diffused cerebral edema | 4 |
| 3 | 36–40 | 97 | MCS | Bilateral frontal hemorrhage | 4 |
| 4 | 56–60 | 113 | MCS | Left frontal, temporal, and occipital hemorrhage with midline shift | 4 |
| 5 | 81–85 | 116 | MCS | Bilateral frontal hemorrhage | 4 |
| 6 | 16–20 | 104 | MCS | Diffused cerebral edema | 5 |
| 7 | 51–55 | 96 | MCS | Left frontal hemorrhage, left frontoparietal white matter hyperintensity | 5 |
| 8 | 66–70 | 294 | MCS | Left frontotemporal, right frontal hemorrhage | 4 |
| 9 | 81–85 | 94 | MCS | Bilateral frontal hemorrhage | 4 |
| 10 | 81–85 | 95 | MCS | Left frontal and temporal hemorrhage, left sub-dural hematoma with midline shift | 4 |
CRS-R and AES in patients before and after the treatments.
| ID | CRS-R | AES | ||||
| Pre-A | Pre-B | Post-B | Pre-A | Pre-B | Post-B | |
| 1 | 14 | 15 | 19 | 18 | 18 | 42 |
| 2 | 14 | 14 | 18 | 18 | 19 | 43 |
| 3 | 14 | 14 | 18 | 18 | 18 | 42 |
| 4 | 15 | 15 | 18 | 18 | 18 | 46 |
| 5 | 15 | 16 | 19 | 18 | 19 | 52 |
| 6 | 16 | 17 | 19 | 18 | 19 | 56 |
| 7 | 17 | 17 | 21 | 18 | 19 | 54 |
| 8 | 14 | 14 | 17 | 18 | 18 | 41 |
| 9 | 15 | 15 | 19 | 18 | 18 | 47 |
| 10 | 14 | 14 | 18 | 18 | 18 | 42 |
FIGURE 2Altered CRS-R and AES in patients before and after treatments. **Significant p-value: p < 0.01. The results showed that CRS-R and AES were improved significantly after treatments.
Changes in the ApEn difference between painful stimuli conditions and eyes-closed condition before and after the treatments.
| Montage | Under affected painful stimuli conditions | Under unaffected painful stimuli conditions | ||||||||||
| Pre-A | Pre-B | Pre-B | Post-B | Pre-A | Pre-B | Pre-B | Post-B | |||||
| FPA | −0.03 ± 0.08 | −0.05 ± 0.07 | 0.824 | −0.05 ± 0.07 | 0.01 ± 0.13 | 0.229 | −0.05 ± 0.09 | −0.02 ± 0.10 | 0.559 | −0.02 ± 0.10 | 0.07 ± 0.08 | 0.096 |
| FPU | −0.04 ± 0.07 | 0.02 ± 0.13 | 0.272 | 0.02 ± 0.13 | 0.04 ± 0.11 | 0.663 | 0.01 ± 0.07 | 0.05 ± 0.11 | 0.197 | 0.05 ± 0.11 | 0.09 ± 0.08 | 0.477 |
| FA | −0.04 ± 0.09 | −0.07 ± 0.08 | 0.182 | −0.07 ± 0.08 | −0.00 ± 0.11 | 0.198 | −0.01 ± 0.07 | −0.03 ± 0.08 | 0.347 | −0.03 ± 0.08 | 0.04 ± 0.06 | 0.129 |
| FU | 0.03 ± 0.11 | 0.05 ± 0.10 | 0.277 | 0.05 ± 0.10 | 0.04 ± 0.11 | 0.906 | 0.04 ± 0.10 | 0.10 ± 0.08 | 0.782 | 0.10 ± 0.08 | 0.13 ± 0.11 | 0.268 |
| CA | −0.02 ± 0.05 | −0.03 ± 0.08 | 0.128 | −0.03 ± 0.08 | −0.01 ± 0.08 | 0.657 | 0.01 ± 0.08 | 0.02 ± 0.08 | 0.512 | 0.02 ± 0.08 | 0.05 ± 0.07 | 0.328 |
| CU | 0.04 ± 0.09 | 0.04 ± 0.13 | 0.695 | 0.04 ± 0.13 | 0.07 ± 0.07 | 0.645 | 0.06 ± 0.11 | 0.06 ± 0.11 | 0.782 | 0.06 ± 0.11 | 0.12 ± 0.08 | 0.273 |
| PA | −0.03 ± 0.07 | −0.05 ± 0.10 | 0.295 | −0.05 ± 0.10 | 0.01 ± 0.10 | 0.297 | 0.01 ± 0.08 | 0.01 ± 0.09 | 0.769 | 0.01 ± 0.09 | 0.08 ± 0.08 | |
| PU | 0.03 ± 0.06 | 0.04 ± 0.05 | 0.826 | 0.04 ± 0.05 | 0.07 ± 0.08 | 0.376 | 0.07 ± 0.08 | 0.11 ± 0.07 | 0.603 | 0.11 ± 0.07 | 0.10 ± 0.11 | 0.787 |
| OA | −0.01 ± 0.09 | −0.05 ± 0.15 | 0.282 | −0.05 ± 0.15 | 0.01 ± 0.10 | 0.189 | −0.04 ± 0.08 | −0.01 ± 0.13 | 0.351 | −0.01 ± 0.13 | 0.08 ± 0.08 | 0.099 |
| OU | −0.04 ± 0.09 | 0.01 ± 0.09 | 0.545 | 0.01 ± 0.09 | 0.11 ± 0.12 | 0.157 | 0.03 ± 0.08 | 0.07 ± 0.09 | 0.782 | 0.07 ± 0.09 | 0.12 ± 0.11 | 0.398 |
| ATA | −0.05 ± 0.08 | −0.07 ± 0.10 | 0.174 | −0.07 ± 0.10 | −0.01 ± 0.14 | 0.324 | −0.01 ± 0.08 | −0.03 ± 0.09 | 0.729 | −0.03 ± 0.09 | 0.01 ± 0.08 | 0.228 |
| ATU | 0.04 ± 0.10 | 0.06 ± 0.11 | 0.159 | 0.06 ± 0.11 | 0.09 ± 0.09 | 0.539 | 0.02 ± 0.10 | 0.08 ± 0.13 | 0.855 | 0.08 ± 0.13 | 0.11 ± 0.12 | 0.722 |
| MTA | −0.02 ± 0.08 | −0.06 ± 0.09 | 0.179 | −0.06 ± 0.09 | 0.03 ± 0.16 | 0.105 | −0.01 ± 0.10 | −0.06 ± 0.15 | 0.169 | −0.06 ± 0.15 | 0.06 ± 0.11 | |
| MTU | 0.07 ± 0.09 | 0.08 ± 0.09 | 0.272 | 0.08 ± 0.09 | 0.10 ± 0.16 | 0.758 | 0.06 ± 0.15 | 0.08 ± 0.11 | 0.549 | 0.08 ± 0.11 | 0.17 ± 0.12 | 0.125 |
| PTA | −0.03 ± 0.16 | −0.03 ± 0.16 | 0.365 | −0.03 ± 0.16 | 0.04 ± 0.12 | 0.265 | 0.01 ± 0.11 | 0.04 ± 0.17 | 0.434 | 0.04 ± 0.17 | 0.07 ± 0.09 | 0.566 |
| PTU | 0.06 ± 0.11 | 0.07 ± 0.12 | 0.760 | 0.07 ± 0.12 | 0.12 ± 0.10 | 0.425 | 0.08 ± 0.10 | 0.09 ± 0.13 | 0.729 | 0.09 ± 0.13 | 0.14 ± 0.09 | 0.350 |
FIGURE 3ApEn index under the affected painful-stimuli condition.
FIGURE 4ApEn index under the unaffected painful-stimuli condition. *p < 0.05 was considered statistically significant.
Changes in the C-ApEn difference between painful stimuli conditions and eyes-closed condition before and after the treatments.
| Montage | Under affected painful stimuli conditions | Under unaffected painful stimuli conditions | ||||||||||
| Pre-A | Pre-B | Pre-B | Post-B | Pre-A | Pre-B | Pre-B | Post-B | |||||
| CA-FA | −0.04 ± 0.06 | −0.06 ± 0.07 | 0.512 | −0.06 ± 0.07 | 0.01 ± 0.08 | 0.128 | −0.01 ± 0.05 | −0.01 ± 0.06 | 0.214 | −0.01 ± 0.06 | 0.06 ± 0.07 | |
| CA-PA | −0.04 ± 0.07 | −0.06 ± 0.07 | 0.761 | −0.06 ± 0.07 | 0.05 ± 0.09 | −0.01 ± 0.05 | −0.03 ± 0.08 | 0.654 | −0.03 ± 0.08 | 0.09 ± 0.10 | ||
| CA-MTA | −0.03 ± 0.06 | −0.04 ± 0.07 | 0.681 | −0.04 ± 0.07 | 0.05 ± 0.11 | 0.081 | −0.03 ± 0.04 | −0.02 ± 0.07 | 0.594 | −0.02 ± 0.07 | 0.09 ± 0.09 | |
| CA-FPA | −0.03 ± 0.08 | −0.04 ± 0.09 | 0.824 | −0.04 ± 0.09 | 0.01 ± 0.10 | 0.272 | −0.01 ± 0.06 | −0.02 ± 0.06 | 0.813 | −0.02 ± 0.06 | 0.06 ± 0.08 | 0.062 |
| CA-OA | −0.02 ± 0.09 | −0.05 ± 0.09 | 0.729 | −0.05 ± 0.09 | 0.04 ± 0.07 | 0.081 | −0.02 ± 0.07 | −0.02 ± 0.09 | 0.782 | −0.02 ± 0.09 | 0.07 ± 0.07 | |
| CU-FU | 0.01 ± 0.08 | 0.03 ± 0.06 | 0.471 | 0.03 ± 0.06 | 0.09 ± 0.06 | 0.03 ± 0.09 | 0.04 ± 0.07 | 0.437 | 0.04 ± 0.07 | 0.14 ± 0.06 | ||
| CU-PU | 0.02 ± 0.09 | 0.03 ± 0.07 | 0.247 | 0.03 ± 0.07 | 0.10 ± 0.08 | 0.060 | 0.04 ± 0.10 | 0.06 ± 0.08 | 0.849 | 0.06 ± 0.08 | 0.14 ± 0.08 | |
| CU-MTU | 0.03 ± 0.09 | 0.04 ± 0.09 | 0.622 | 0.04 ± 0.09 | 0.13 ± 0.10 | 0.04 ± 0.09 | 0.06 ± 0.07 | 0.834 | 0.06 ± 0.07 | 0.16 ± 0.08 | ||
| CU-FPU | 0.03 ± 0.09 | 0.04 ± 0.08 | 0.665 | 0.04 ± 0.08 | 0.08 ± 0.07 | 0.305 | 0.03 ± 0.09 | 0.05 ± 0.08 | 0.225 | 0.05 ± 0.08 | 0.14 ± 0.07 | |
| CU-OU | 0.01 ± 0.08 | 0.03 ± 0.07 | 0.842 | 0.03 ± 0.07 | 0.10 ± 0.09 | 0.069 | 0.03 ± 0.11 | 0.05 ± 0.08 | 0.645 | 0.05 ± 0.08 | 0.17 ± 0.08 | |
FIGURE 5C-ApEn index under the affected painful-stimuli condition. *p < 0.05 was considered statistically significant.
FIGURE 6C-ApEn index under the unaffected painful-stimuli condition. *p < 0.05 was considered statistically significant.
Relevant factors of CRS-R improvement.
| Model | Unstandardized coefficient | Standardized coefficienth | |||
| B | Standard error | b | |||
| Constant | 4.16 | 0.03 | 148.71 | ||
| Improvement in CA-PA (APS) | −7.34 | 0.07 | −1.22 | −103.63 | |
| Improvement in CA-FA (APS) | 4.91 | 0.08 | 0.85 | 60.02 | |
| Improvement in FA (APS) | −2.11 | 0.06 | −0.42 | −33.62 | |
| Improvement in CU (APS) | −0.41 | 0.05 | −0.08 | −7.66 | |
| Gender | −0.06 | 0.02 | −0.04 | −3.47 | |
Relevant factors of AES improvement.
| Model | Unstandardized coefficient | Standardized coefficient | |||
| B | Standard error | b | |||
| Constant | 31.03 | 1.00 | 30.91 | ||
| Improvement of CA-FPA (UPS) | −70.43 | 7.85 | −0.90 | −8.97 | |
| Improvement of CU-FU (APS) | 58.16 | 10.61 | 0.55 | 5.48 | |
| Improvement of CA (APS) | 12.80 | 4.01 | 0.31 | 3.19 | |